This approval extends the benefit of VELCADE for mantle cell lymphoma (MCL) to previously untreated patients in addition to relapsed or refractory patients First treatment approved by the U.S. Food ...

"Results from this trial build on the growing body of data showing that VELCADE based regimens deliver high CR rates that translate to increased post- transplantation benefits," said Nancy Simonian, M ...

Phase III Trial of VELCADE for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma - VELCADE, ...

VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of ...

Previous studies in relapsed MM have demonstrated single-agent VELCADE has an unprecedented survival advantage. In newly diagnosed patients, VELCADE based therapies have achieved transplant-like ...

HIGH WYCOMBE, UK, 28th April 2005 – Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced that the European Commission has approved the use of VELCADE® (bortezomib) for ...

CAMBRIDGE, Mass., May 16 Millennium Pharmaceuticals, TheTakeda Oncology Company, today announced that new data from VELCADE clinicalstudies are scheduled to be featured at the 2008 American Society of ...

Findings published in the April 15th issue of Blood show that a team of researchers led by Millennium Pharmaceuticals, Inc. has discovered biomarkers which may lead to identifying multiple myeloma ...

Co reported on the presentation of results from clinical trials of Velcade based therapies that showed high complete remission / complete response rates in previously treated multiple myeloma patients ...

CAMBRIDGE, Mass., Nov. 18 Millennium: The Takeda OncologyCompany today announced that 120 data presentations concerning VELCADEresearch will be featured at the 50th American Society of Hematology (ASH ...